Selected article for: "medicinal chemistry and small molecule"

Author: Nikolaou, Aikaterini; Kokotou, Maroula G.; Vasilakaki, Sofia; Kokotos, George
Title: Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A(2)()
  • Cord-id: 00dxpxox
  • Document date: 2018_8_23
  • ID: 00dxpxox
    Snippet: Phospholipase A(2) (PLA(2)) enzymes are involved in various inflammatory pathological conditions including arthritis, cardiovascular and autoimmune diseases. The regulation of their catalytic activity is of high importance and a great effort has been devoted in developing synthetic inhibitors. We summarize the most important small-molecule synthetic PLA(2) inhibitors developed to target each one of the four major types of human PLA(2) (cytosolic cPLA(2), calcium-independent iPLA(2,) secreted sPL
    Document: Phospholipase A(2) (PLA(2)) enzymes are involved in various inflammatory pathological conditions including arthritis, cardiovascular and autoimmune diseases. The regulation of their catalytic activity is of high importance and a great effort has been devoted in developing synthetic inhibitors. We summarize the most important small-molecule synthetic PLA(2) inhibitors developed to target each one of the four major types of human PLA(2) (cytosolic cPLA(2), calcium-independent iPLA(2,) secreted sPLA(2,) and lipoprotein-associated LpPLA(2)). We discuss recent applications of inhibitors to understand the role of each PLA(2) type and their therapeutic potential. Potent and selective PLA(2) inhibitors have been developed. Although some of them have been evaluated in clinical trials, none reached the market yet. Apart from their importance as potential medicinal agents, PLA(2) inhibitors are excellent tools to unveil the role that each PLA(2) type plays in cells and in vivo. Modern medicinal chemistry approaches are expected to generate improved PLA(2) inhibitors as new agents to treat inflammatory diseases.

    Search related documents:
    Co phrase search for related documents
    • active site and additional one: 1
    • active site and adme property: 1
    • active site and liver injury: 1
    • active site and low micromolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • active site and low molecular weight: 1, 2, 3, 4
    • active site and lower fold: 1, 2, 3
    • activity level and acute coronary syndrome: 1, 2, 3
    • activity level and ad disease: 1, 2, 3, 4
    • activity level and liver injury: 1, 2
    • activity level and long chain: 1
    • activity level and low molecular weight: 1
    • activity level and lps induce: 1, 2
    • liver injury and low molecular weight: 1
    • liver injury and lps induce: 1, 2, 3
    • liver injury and lps stimulate: 1